351 related articles for article (PubMed ID: 34944682)
1. Metabolic Associated Fatty Liver Disease in Children-From Atomistic to Holistic.
Mărginean CO; Meliț LE; Săsăran MO
Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944682
[TBL] [Abstract][Full Text] [Related]
2. MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis.
Segura-Azuara NLÁ; Varela-Chinchilla CD; Trinidad-Calderón PA
Front Med (Lausanne); 2021; 8():774079. PubMed ID: 35096868
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem.
Le Garf S; Nègre V; Anty R; Gual P
Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944730
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases.
Gutiérrez-Cuevas J; Santos A; Armendariz-Borunda J
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769060
[TBL] [Abstract][Full Text] [Related]
5. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?
Kjær MB; George J; Kazankov K; Grønbæk H
Expert Rev Gastroenterol Hepatol; 2021 Jan; 15(1):51-64. PubMed ID: 32878486
[TBL] [Abstract][Full Text] [Related]
6. A Review of the Increasing Prevalence of Metabolic-Associated Fatty Liver Disease (MAFLD) in Children and Adolescents Worldwide and in Mexico and the Implications for Public Health.
Ramírez-Mejía MM; Díaz-Orozco LE; Barranco-Fragoso B; Méndez-Sánchez N
Med Sci Monit; 2021 Aug; 27():e934134. PubMed ID: 34456329
[TBL] [Abstract][Full Text] [Related]
7. Low levels of Lysosomal Acid Lipase (LAL) activity increases necroinflammation in adult patients with biopsy-proven metabolic associated fatty liver disease.
Thoen RU; Longo L; Neto SC; Álvares-da-Silva MR
Clin Res Hepatol Gastroenterol; 2021 Nov; 45(6):101638. PubMed ID: 33662773
[TBL] [Abstract][Full Text] [Related]
8. Updates in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Children.
Rupasinghe K; Hind J; Hegarty R
J Pediatr Gastroenterol Nutr; 2023 Nov; 77(5):583-591. PubMed ID: 37592398
[TBL] [Abstract][Full Text] [Related]
9. Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives.
Vimalesvaran S; Vajro P; Dhawan A
Hepatol Int; 2024 Jun; ():. PubMed ID: 38879851
[TBL] [Abstract][Full Text] [Related]
10. Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study.
Baratta F; Ferro D; Pastori D; Colantoni A; Cocomello N; Coronati M; Angelico F; Del Ben M
Int J Environ Res Public Health; 2021 Aug; 18(17):. PubMed ID: 34501590
[TBL] [Abstract][Full Text] [Related]
11. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD.
Yamamura S; Eslam M; Kawaguchi T; Tsutsumi T; Nakano D; Yoshinaga S; Takahashi H; Anzai K; George J; Torimura T
Liver Int; 2020 Dec; 40(12):3018-3030. PubMed ID: 32997882
[TBL] [Abstract][Full Text] [Related]
12. Metabolic-Associated Fatty Liver Disease: A Disastrous Human Health Challenge.
Fouda S; Pappachan JM
Endocrinol Metab Clin North Am; 2023 Sep; 52(3):xv-xvi. PubMed ID: 37495346
[TBL] [Abstract][Full Text] [Related]
13. New Perspectives on Genetic Prediction for Pediatric Metabolic Associated Fatty Liver Disease.
Lin YC; Wu CC; Ni YH
Front Pediatr; 2020; 8():603654. PubMed ID: 33363067
[TBL] [Abstract][Full Text] [Related]
14. Infections at the nexus of metabolic-associated fatty liver disease.
Boeckmans J; Rombaut M; Demuyser T; Declerck B; Piérard D; Rogiers V; De Kock J; Waumans L; Magerman K; Cartuyvels R; Rummens JL; Rodrigues RM; Vanhaecke T
Arch Toxicol; 2021 Jul; 95(7):2235-2253. PubMed ID: 34027561
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and predicting factors of metabolic-associated fatty liver disease diagnosed by transient elastography with controlled attenuation parameters in HIV-positive people.
Jongraksak T; Sobhonslidsuk A; Jatchavala J; Warodomwichit D; Kaewduang P; Sungkanuparph S
Int J STD AIDS; 2021 Mar; 32(3):266-275. PubMed ID: 33334267
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study.
Chen YL; Li H; Li S; Xu Z; Tian S; Wu J; Liang XY; Li X; Liu ZL; Xiao J; Wei JY; Ma CY; Wu KN; Ran L; Kong LQ
BMC Gastroenterol; 2021 May; 21(1):212. PubMed ID: 33971822
[TBL] [Abstract][Full Text] [Related]
17. MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD.
Meroni M; Longo M; Fracanzani AL; Dongiovanni P
EBioMedicine; 2020 Jul; 57():102866. PubMed ID: 32629394
[TBL] [Abstract][Full Text] [Related]
18. Updates in fatty liver disease: Pathophysiology, diagnosis and management.
Gofton C; George J
Aust J Gen Pract; 2021 Oct; 50(10):702-707. PubMed ID: 34590082
[TBL] [Abstract][Full Text] [Related]
19. Circulating angiopoietin-like proteins in metabolic-associated fatty liver disease: a systematic review and meta-analysis.
Ke Y; Liu S; Zhang Z; Hu J
Lipids Health Dis; 2021 May; 20(1):55. PubMed ID: 34034750
[TBL] [Abstract][Full Text] [Related]
20. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease.
Wu YL; Kumar R; Wang MF; Singh M; Huang JF; Zhu YY; Lin S
World J Gastroenterol; 2021 Sep; 27(34):5753-5763. PubMed ID: 34629799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
